As of 2022, around 42 percent of all Humira U.S. sales are expected to be at risk due to the drug patent expiring in 2023. This statistic illustrates the share of sales at risk of pharmaceutical products in the U.S. due to approaching drug patent expiries.
Sales share of leading pharmaceutical products at risk in the U.S. due to approaching drug patent expiries as of 2022
Product, company (year of patent loss)
Share of sales
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Exclusive Premium Statistic
To access all Premium Statistics, you need a paid Statista Account
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how Statista can support your business.
Evaluate Vantage. (May 25, 2022). Sales share of leading pharmaceutical products at risk in the U.S. due to approaching drug patent expiries as of 2022 [Graph]. In Statista. Retrieved July 22, 2024, from https://www.statista.com/statistics/1315621/sales-share-at-risk-of-top-drugs-due-to-us-patent-expiries/
Evaluate Vantage. "Sales share of leading pharmaceutical products at risk in the U.S. due to approaching drug patent expiries as of 2022." Chart. May 25, 2022. Statista. Accessed July 22, 2024. https://www.statista.com/statistics/1315621/sales-share-at-risk-of-top-drugs-due-to-us-patent-expiries/
Evaluate Vantage. (2022). Sales share of leading pharmaceutical products at risk in the U.S. due to approaching drug patent expiries as of 2022. Statista. Statista Inc.. Accessed: July 22, 2024. https://www.statista.com/statistics/1315621/sales-share-at-risk-of-top-drugs-due-to-us-patent-expiries/
Evaluate Vantage. "Sales Share of Leading Pharmaceutical Products at Risk in The U.S. Due to Approaching Drug Patent Expiries as of 2022." Statista, Statista Inc., 25 May 2022, https://www.statista.com/statistics/1315621/sales-share-at-risk-of-top-drugs-due-to-us-patent-expiries/
Evaluate Vantage, Sales share of leading pharmaceutical products at risk in the U.S. due to approaching drug patent expiries as of 2022 Statista, https://www.statista.com/statistics/1315621/sales-share-at-risk-of-top-drugs-due-to-us-patent-expiries/ (last visited July 22, 2024)
Sales share of leading pharmaceutical products at risk in the U.S. due to approaching drug patent expiries as of 2022 [Graph], Evaluate Vantage, May 25, 2022. [Online]. Available: https://www.statista.com/statistics/1315621/sales-share-at-risk-of-top-drugs-due-to-us-patent-expiries/
